Trials / Completed
CompletedNCT01217008
Safety Study of GRNOPC1 in Spinal Cord Injury
A Phase 1 Safety Study of GRNOPC1 in Patients With Neurologically Complete, Subacute, Spinal Cord Injury
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Lineage Cell Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GRNOPC1 | One injection of 2 million GRNOPC1 cells. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2010-10-08
- Last updated
- 2020-06-18
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01217008. Inclusion in this directory is not an endorsement.